.png)
Midsize Biotech
Market Access, HEOR Clinical Development, Commercial Strategy
Next-generation metabolic therapy
Obesity
Subscribe to our newsletter to receive the latest case studies.
Midsize Biotech
Market Access, HEOR Clinical Development, Commercial Strategy
Next-generation metabolic therapy
Obesity
The client was developing a next-generation metabolic therapy in an obesity market that was changing rapidly.
Traditional payer decision drivers, weight loss magnitude alone, were no longer sufficient. Payers were increasingly focused on durability, metabolic health, functional outcomes, and the quality of weight loss over time.
The client engaged Alkemi to anticipate how payer expectations were evolving and to align their development strategy and target product profile with future access requirements.
1. Reviewed payer policies, coverage trends, and existing evidence to understand current and emerging decision drivers in obesity.
2. Conducted primary payer research to assess how next-generation therapies would be evaluated over the coming years.
3. Synthesized insights into a structured Obesity Value Framework outlining future payer priorities and evidence expectations.
4. Translated implications into clear strategic guidance for TPP refinement and Phase II/III trial design.
Design evidence today that will still matter when the product reaches market.
“The collaboration was immensely valuable and truly helped shape our understanding and positioning in obesity.” - Head of Market Access
Identified the shift toward evaluating durability, metabolic outcomes, and quality of weight loss.
Enabled refinement of the TPP and prioritization of endpoints aligned with future payer expectations.
Positioned the program to enter later-stage development with evidence designed to support reimbursement, not just approval.